newsfilter
← Latest News
GlobeNewswire·

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 Positive top-l